Complement (C3, C4) and C-reactive protein responses to cardiopulmonary bypass and protamine administration

M Tulunay1, S Demiralp, S Tastan

  • 1Department of Anaesthesiology, Ibn-i Sina Hospital, University of Ankara, Turkey.

Insights

Cardiopulmonary bypass (CPB) activates the complement system, primarily via the classic pathway, without significantly altering C-reactive protein (CRP) levels during the procedure. Protamine administration did not further activate complement.

Area of Science:

  • Immunology
  • Cardiovascular Surgery

Background:

  • Complement activation is implicated in cardiopulmonary bypass (CPB)-associated damage during open heart surgery.
  • The study investigates complement system components C3, C4, and C-reactive protein (CRP) in patients undergoing CPB.

Purpose of the Study:

  • To assess the impact of CPB and protamine administration on complement activation.
  • To evaluate changes in C3, C4, and CRP levels during and after CPB.

Main Methods:

  • Studied 22 patients undergoing CPB, divided into two groups based on protamine administration route (intravenous vs. aortic root).
  • Measured serum levels of C3, C4, and CRP at various time points.

Main Results:

  • Significant decreases in C3 and C4 observed during CPB, indicating classic pathway activation.
  • Protamine did not induce further complement activation.
  • C3 levels normalized within 24 hours post-CPB, while C4 remained lower.
  • CRP levels showed no significant change during CPB but increased 24 hours post-operation.

Conclusions:

  • CPB activates the complement system, but the duration may not be sufficient to trigger an acute phase response indicated by CRP increase.
  • Protamine administration does not exacerbate complement activation in this context.

Related Concept Videos

Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...